Table 2. Median fluorescence intensity (MFI) of CD86 and MHC class II on CD19⁺ or CD11c⁺ cells in spleen post Matrix-M™ treatment.

Spleen		CD86 (×103)		MHC class II (×103)
		24 h	48 h	24 h	48 h
CD19	PBS	0.9±0.02	0.9±0.02	28±4	31±3
	Matrix-M™ 3 µg	0.9±0.03	1.1±0.06	28±3	31±3
	Matrix-M™ 12 µg	1.0±0.04**	1.2±0.04**	27±3	30±2
	Matrix-M™ 30 µg	0.9±0.03	1.3±0.1***	23±3*	33±4
CD11c	PBS	1.6±0.2	1.5±0.2	46±8	48±4
	Matrix-M™ 3 µg	1.7±0.3	1.7±0.3	47±7	44±5
	Matrix-M™ 12 µg	2.0±0.4	3.1±0.2**	47±5	40±2*
	Matrix-M™ 30 µg	2.4±0.5***	3.0±0.9***	49±6	41±6*

Mice were injected subcutaneously at the base of the tail and the spleen was harvested and analyzed as described in Materials and Methods. Data is shown as mean ± SD (n = 6–8 mice). Significant differences from PBS treatment using Kruskal-Wallis test with Dunn's posttest are outlined with *, p<0.05; **, p<0.01; ***, p<0.001.